Cancer Neoantigens, Vaccines and Viruses

癌症新抗原、疫苗和病毒

• 批准号: 10233861
• 负责人: Thale Cross Jarvis
• 金额: $ 0.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10233861
• 关键词: Address; Antigen Targeting; Antitumor Response; Area; Basic Science; Canada; Cancer Vaccines; Clinic; Clinical; Clinical Sciences; Collaborations; Conflict (Psychology); Development; Disease; Educational workshop; Future; Immunology; Immunotherapeutic agent; Immunotherapy; Industrialization; Knowledge; Learning; Malignant Neoplasms; Methodology; Methods; Modality; Modeling; Outcome; Research; Research Personnel; Scientific Advances and Accomplishments; Scientist; Speed; T-Lymphocyte; Technology; Therapeutic; Translations; Tumor Antigens; Tumor Immunity; Vaccines; Viral; Viral Antigens; Viral Cancer; Virus; Work; base; cancer immunotherapy; clinical implementation; clinical practice; design; insight; interest; learning network; meetings; multidisciplinary; neoantigen vaccine; neoantigens; next generation; novel; novel strategies; novel therapeutic intervention; posters; programs; symposium; tumor; tumor microenvironment; vaccine platform

ABSTRACT Support is requested for a Keystone Symposia conference entitled Cancer Neoantigens, Vaccines and Viruses, organized by Drs. Catherine J. Wu, Robert D. Schreiber and Cornelis J.M. Melief. The conference will be held in Vancouver, BC Canada from June 27- July 1, 2021. Advances in cancer immunotherapy are rapidly transforming the treatment landscape across cancers, but a critical challenge in the field is understanding how we can better drive T cells into tumors, and hence make them available for mounting productive anti-tumor responses. The fields of viral and cancer immunity share many parallels, and insights learned from each area can expand our collective knowledge of how to address this challenge. Cancer vaccines are a valuable immunotherapeutic modality, capable of expanding the repertoire of tumor-specific T cells and have the potential to be productively combined with complementary therapeutic approaches. This conference program was designed to highlight the exciting recent clinical and scientific advances, including the identification of novel antigen targets, new understanding of how the tumor microenvironment is immunoregulated and modulated by cancer immunotherapies, and the development of novel therapeutic approaches. Together, the collective shared knowledge gained from interdisciplinary interactions from this meeting promise to open the path for consideration of novel approaches for the design of more effective cancer immunotherapies.

摘要 要求为题为“癌症新抗原、疫苗和免疫”的Keystone专题讨论会提供支助。 病毒，由凯瑟琳J吴博士，罗伯特D。Schreiber和Cornelis J.M.梅利耶夫会议将 将于2021年6月27日至7月1日在加拿大不列颠哥伦比亚省温哥华举行。 癌症免疫治疗的进展正在迅速改变癌症的治疗前景，但 该领域的一个关键挑战是了解我们如何更好地将T细胞驱动到肿瘤中，从而使 它们可用于产生有效的抗肿瘤反应。病毒免疫和癌症免疫领域 许多相似之处，以及从每个领域学到的见解，可以扩大我们对如何解决 这个挑战。癌症疫苗是一种有价值的免疫方式，能够扩大免疫原性。 肿瘤特异性T细胞的库，并具有与互补的T细胞有效结合的潜力。 治疗方法。本次会议计划旨在突出最近令人兴奋的临床和 科学进步，包括新抗原靶点的鉴定，对肿瘤如何 微环境受到癌症免疫疗法的免疫调节和调节， 新的治疗方法。在一起，集体共享从跨学科获得的知识， 这次会议的互动承诺为考虑新的设计方法开辟道路， 更有效的癌症免疫疗法。